HC Wainwright & Co. maintains Sierra Oncology (NASDAQ:SRRA) with a Buy and raises the price target from $29 to $35.
August 6, 8:06 AM
Sierra Oncology Inc (NASDAQ:SRRA) has acquired an exclusive global license from AstraZeneca Plc (NASDAQ:AZN) for AZD5153, a potent, and selective BRD4 BET inhibitor…
The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
August 6, 7:42 AM
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 5)
August 5, 4:52 PM
Sierra Oncology (NASDAQ:SRRA) reported quarterly losses of $(1.67) per share. This is a 5.7 percent decrease over losses of $(1.58) per share from the same period last year.
Sierra Oncology Signs Exclusive Global In-Licensing Agreement With AstraZeneca For Novel BET Inhibitor To Expand Myelofibrosis Pipeline
August 5, 4:30 PM
Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, today announced it has acquired an exclusive global license from
June 21, 7:00 AM
Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, today announced the completion of enrollment for its pivotal Phase 3
Pharma/Biotech Companies Highlight Upcoming Presentations At American Society Of Clinical Oncology Jun. 4-8, 2021
May 19, 5:25 PM
Cullinan Oncology (CGEM) - https://www.globenewswire.com/news-release/2021/05/19/2232874/0/en/Cullinan-Oncology-to-Provide-CLN-081-Clinical-Update-at-ASCO-2021.html BeiGene (BGNE)